Partial
Partially Aligned
Patient Risk:
Low
Summary
Most dosing/strength and general once-daily use details are supported by the label excerpts, but the proposed titration/starting-dose range and missed-dose instructions are not supported by the provided labeling text.
Category Scores
Accurate Statements
Lipitor (atorvastatin) is prescribed in tablet strengths of 10 mg, 20 mg, 40 mg, and 80 mg.
Label section 3 (DOSAGE FORMS AND STRENGTHS): tablets containing 10, 20, 40, 80 mg atorvastatin calcium.
Lipitor (atorvastatin) is taken by mouth once daily.
Label section 2.1: recommended starting dose 10 or 20 mg once daily; dosage range 10 to 80 mg once daily; administered as a single dose at any time of the day, with or without food.
The Lipitor (atorvastatin) dose can be increased up to 80 mg once daily when needed for further LDL-cholesterol reduction.
Label section 2.1: dosage range 10 to 80 mg once daily.
Unsupported Statements
Clinicians start Lipitor (atorvastatin) with a daily dose in the 10–20 mg range for most patients.
Label excerpt specifies recommended starting dose is 10 or 20 mg once daily, but does not state this is used for 'most patients.'
The Lipitor (atorvastatin) dose is adjusted based on the response of cholesterol levels and the patient’s cardiovascular risk.
Provided excerpts do not describe titration being based on both cholesterol response and cardiovascular risk.
If a Lipitor (atorvastatin) dose is missed, it should be taken when remembered unless it is close to the time of the next dose.
No missed-dose instructions are present in the provided label excerpts.
If a Lipitor (atorvastatin) dose is missed, two doses should not be taken at the same time.
No missed-dose instructions are present in the provided label excerpts.
Contradictions
Important Omissions
Label-supported alternative/expanded initiation guidance (e.g., 'Patients who require a large reduction in LDL-C (more than 45%) may be started at 40 mg once daily') is not reflected in the AI response's description of starting doses.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Low
The response includes generally label-consistent strength and once-daily dosing; main potential issues are unsupported specifics (titration rationale and missed-dose instructions), which could lead to inaccuracies in medication use if treated as authoritative.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Medium |
Recommendation
Partially Aligned
Primary Issue
Missed-dose instructions and titration rationale ('based on cholesterol response and cardiovascular risk') are not supported by the provided label excerpts.
Suggested Improvement
Limit statements to what the label excerpts support (e.g., tablet strengths and once-daily 10–80 mg range; recommended starting dose is 10 or 20 mg once daily; note that label supports starting at 40 mg once daily for patients requiring a large LDL-C reduction). Omit missed-dose guidance unless corresponding label language is provided.